Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription Articles published in BJU Int Retrieve available abstracts of 231 articles: HTML format

Single Articles

June 2024
1. 
   Prostate cancer: To screen, or not to screen? That is the question.
   BJU Int. 2024;133:635-637.
   PubMed    
   
   
   
2. FRANCO A, Ditonno F, Manfredi C, Licari LC, et al
   Robot-assisted single-port transvesical enucleation of the prostate: step-by-step technique and early single-centre experience.
   BJU Int. 2024;133:778-782.
   PubMed    
   
   
   
3. NOLSOE AB, Ostergren PB, Jakobsen H, Jensen CFS, et al
   Can nerve monitoring during radical prostatectomy improve functional outcomes? A randomised trial.
   BJU Int. 2024;133:742-751.
   PubMed     Abstract available
   
   
   
4. MAURER J, Friedemann T, Chen Y, Ambrosini F, et al
   A randomized controlled study on acupuncture for peri-operative pain after open radical prostatectomy.
   BJU Int. 2024;133:725-732.
   PubMed     Abstract available
   
   
   
5. LENFANT L, Beitone C, Troccaz J, Roupret M, et al
   Learning curve for fusion magnetic resonance imaging targeted prostate biopsy and three-dimensional transrectal ultrasonography segmentation.
   BJU Int. 2024;133:709-716.
   PubMed     Abstract available
   
   
   
6. ALMEIDA-MAGANA R, Au M, Al-Hammouri T, Dinneen K, et al
   Improving fluorescence confocal microscopy for margin assessment during robot-assisted radical prostatectomy: The LaserSAFE technique.
   BJU Int. 2024;133:677-679.
   PubMed    
   
   
   
7. MAC CURTAIN BM, Sugrue DD, Qian W, O'Callaghan M, et al
   Membranous urethral length and urinary incontinence following robot-assisted radical prostatectomy: a systematic review and meta-analysis.
   BJU Int. 2024;133:646-655.
   PubMed     Abstract available
   
   
   May 2024
8. PELTIER A, van Velthoven R, Baudewyns A, Assenmacher G, et al
   Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective 'ablate-and-resect' study.
   BJU Int. 2024 May 14. doi: 10.1111/bju.16385.
   PubMed     Abstract available
   
   
   
9. BENJAMIN DJ, Yazdanpanah O, Rezazadeh Kalebasty A
   A review of vitamin use for the prevention or treatment of prostate cancer.
   BJU Int. 2024 May 13. doi: 10.1111/bju.16398.
   PubMed    
   
   
   
10. PASANEN N, Talala K, Remmers S, Tammela TLJ, et al
    Which men benefit from prostate cancer screening? Prostate cancer mortality by subgroup in the European Randomised Study of Screening for Prostate Cancer.
    BJU Int. 2024 May 9. doi: 10.1111/bju.16394.
    PubMed     Abstract available
    
    
    
11. GRAJALES V, Martini A, Shore ND
    Complications of immuno-oncology care: what urologist should know.
    BJU Int. 2024;133:524-531.
    PubMed     Abstract available
    
    
    
12. CHALOUPKA M, Pyrgidis N, Ebner B, Volz Y, et al
    Added value of randomised biopsy to multiparametric magnetic resonance imaging-targeted biopsy of the prostate in a contemporary cohort.
    BJU Int. 2024;133:548-554.
    PubMed     Abstract available
    
    
    April 2024
13. SIMHAL RK, Wang KR, Shah YB, Lallas CD, et al
    Peri-operative outcomes following radical prostatectomy in the setting of advanced prostate cancer.
    BJU Int. 2024 Apr 23. doi: 10.1111/bju.16370.
    PubMed     Abstract available
    
    
    
14. STATTIN P, Fleming S, Lin X, Lefresne F, et al
    Population-based study of disease trajectory after radical treatment for high-risk prostate cancer.
    BJU Int. 2024 Apr 15. doi: 10.1111/bju.16362.
    PubMed     Abstract available
    
    
    
15. RODRIGUEZ-SANCHEZ L, Reiter R, Rodriguez A, Emberton M, et al
    The FocAL therapy CONsensus (FALCON): enhancing partial gland ablation for localised prostate cancer.
    BJU Int. 2024 Apr 13. doi: 10.1111/bju.16360.
    PubMed    
    
    
    
16. BERRIDGE C, Omer A, Lopez F, Bryant RJ, et al
    Perspectives on technology - prostate cancer: is local anaesthetic transperineal prostate biopsy really better than transrectal biopsy?
    BJU Int. 2024 Apr 8. doi: 10.1111/bju.16349.
    PubMed     Abstract available
    
    
    
17. VICKERS A
    Magnetic resonance imaging-targeted prostate biopsy changed everything (so everything has to change).
    BJU Int. 2024;133:354-355.
    PubMed    
    
    
    
18. MCNICHOLAS DP, Parr NJ
    Image intensifier-guided transperineal prostate biopsy for patients without a rectum: novel technique.
    BJU Int. 2024;133:487-490.
    PubMed     Abstract available
    
    
    
19. JABBOUR T, Peltier A, Rocq L, Sirtaine N, et al
    Magnetic resonance imaging targeted biopsy in biopsy-naive patients and the risk of overtreatment in prostate cancer: a grading issue.
    BJU Int. 2024;133:432-441.
    PubMed     Abstract available
    
    
    
20. MEHAWED G, Murray R, Rukin NJ, Roberts MJ, et al
    Prostate tumour visualisation with PET: is image fusion with MRI the answer?
    BJU Int. 2024;133 Suppl 4:4-6.
    PubMed    
    
    
    March 2024
21. ALBERTSEN PC
    Response to 'Endpoint and control group in prostate cancer screening research: public health basics'.
    BJU Int. 2024 Mar 30. doi: 10.1111/bju.16357.
    PubMed    
    
    
    
22. TAKAHASHI T
    Endpoint and control group in prostate cancer screening research: public health basics.
    BJU Int. 2024 Mar 29. doi: 10.1111/bju.16356.
    PubMed    
    
    
    
23. PAK JS, Huang R, Huang WC, Lepor H, et al
    Interaction of patient age and high-grade prostate cancer on targeted biopsies of MRI suspicious lesions.
    BJU Int. 2024 Mar 27. doi: 10.1111/bju.16341.
    PubMed     Abstract available
    
    
    
24. PARRY MG, Sujenthiran A, Nossiter J, Morris M, et al
    Reply to: Letter to the editor regarding the article 'Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound'.
    BJU Int. 2024 Mar 22. doi: 10.1111/bju.16348.
    PubMed    
    
    
    
25. HAMDY FC, Albertsen PC, Donovan JL
    Screening and active surveillance in prostate cancer: the dilemma continues.
    BJU Int. 2024 Mar 21. doi: 10.1111/bju.16345.
    PubMed    
    
    
    
26. HUBER J, Karschuck P, Valdix J, Thomas C, et al
    Online decision aid for patients with prostate cancer evaluated by 11 290 patients and 91 urologists in Germany.
    BJU Int. 2024 Mar 20. doi: 10.1111/bju.16329.
    PubMed     Abstract available
    
    
    
27. TAKAHASHI T
    Active surveillance in all cases of screen-detected prostate cancer.
    BJU Int. 2024 Mar 20. doi: 10.1111/bju.16344.
    PubMed    
    
    
    
28. ROKAN N, Reddy D, Dudderidge T
    Focal therapy for prostate cancer - when to refer?
    BJU Int. 2024 Mar 13. doi: 10.1111/bju.16315.
    PubMed    
    
    
    
29. VAN HARTEN MJ, Roobol MJ, van Leeuwen PJ, Willemse PM, et al
    Evolution of European prostate cancer screening protocols and summary of ongoing trials.
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16311.
    PubMed     Abstract available
    
    
    
30. LOFFELER S, Bertilsson H, Muller C, Aas K, et al
    Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged >/=75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P).
    BJU Int. 2024 Mar 12. doi: 10.1111/bju.16314.
    PubMed     Abstract available
    
    
    
31. HONORE A, Moen CA, Juliebo-Jones P, Reisaeter LAR, et al
    Transitioning from transrectal to transperineal prostate biopsy using a freehand cognitive approach.
    BJU Int. 2024;133:324-331.
    PubMed     Abstract available
    
    
    February 2024
32. GEBOERS B, Scheltema MJV, Emmett L, Stricker PD, et al
    Reply to 'Re: Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy'.
    BJU Int. 2024 Feb 28. doi: 10.1111/bju.16308.
    PubMed    
    
    
    
33. LEMANSKA A, Andrews C, Fisher L, Bacon S, et al
    During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England.
    BJU Int. 2024 Feb 27. doi: 10.1111/bju.16305.
    PubMed     Abstract available
    
    
    
34. ZUUR LG, de Barros HA, van Oosterom MN, Berrens AC, et al
    (99m) TcPSMA-radioguided surgery in oligorecurrent prostate cancer: the randomised TRACE-II trial.
    BJU Int. 2024 Feb 12. doi: 10.1111/bju.16297.
    PubMed     Abstract available
    
    
    
35. DE MARIA M, Meneghetti I, Mosillo L, Collins JW, et al
    Versius robotic surgical system: case series of 18 robot-assisted radical prostatectomies.
    BJU Int. 2024;133:197-205.
    PubMed     Abstract available
    
    
    
36. DEARNALEY D, Griffin CL, Silva P, Wilkins A, et al
    International Society of Urological Pathology (ISUP) Gleason Grade Groups stratify outcomes in the CHHiP Phase 3 prostate radiotherapy trial.
    BJU Int. 2024;133:179-187.
    PubMed     Abstract available
    
    
    
37. PTASZNIK G, Kelly BD, Murphy D, Lawrentschuk N, et al
    How prostate-specific membrane antigen positron emission tomography is refining risk calculators in the primary prostate diagnostic pathway.
    BJU Int. 2024;133 Suppl 3:13-14.
    PubMed    
    
    
    
38. ROBERTS MJ, Conduit C, Davis ID, Effeney RM, et al
    The Dedicated Imaging Post-Prostatectomy for Enhanced Radiotherapy outcomes (DIPPER) trial protocol: a multicentre, randomised trial of salvage radiotherapy versus surveillance for low-risk biochemical recurrence after radical prostatectomy.
    BJU Int. 2024;133 Suppl 3:39-47.
    PubMed     Abstract available
    
    
    January 2024
39. SANCHEZ-SALAS R
    Candid choices: optimising patient selection in prostate cancer focal therapy.
    BJU Int. 2024 Jan 20. doi: 10.1111/bju.16270.
    PubMed    
    
    
    
40. BESIROGLU H
    Re: 'Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound'.
    BJU Int. 2024 Jan 18. doi: 10.1111/bju.16277.
    PubMed    
    
    
    
41. TALWAR R, Akinsola O, Penson DF
    What is cancer? A focus on Grade Group 1 prostate cancer.
    BJU Int. 2024 Jan 16. doi: 10.1111/bju.16280.
    PubMed     Abstract available
    
    
    
42. ALBERTSEN PC, Bjerner LJ, Pasovic L, Muller S, et al
    Opportunistic prostate-specific antigen testing in Norwegian men: a public health challenge.
    BJU Int. 2024;133:104-111.
    PubMed     Abstract available
    
    
    
43. MAYOR N, Eldred-Evans D, Tam H, Sokhi H, et al
    Prostagram magnetic resonance imaging in a screening population: Prostate Imaging-Reporting and Data System or Likert?
    BJU Int. 2024;133:112-117.
    PubMed     Abstract available
    
    
    December 2023
44. GUERCIO A, Franco G, Lombardo R, De Nunzio C, et al
    LETTER TO THE EDITOR Prostate-specific membrane antigen positron emission tomography in addition to multiparametric magnetic resonance imaging and biopsies to select prostate cancer patients for focal therapy.
    BJU Int. 2023 Dec 14. doi: 10.1111/bju.16263.
    PubMed    
    
    
    
45. LENI R, Roscigno M, Barzaghi P, La Croce G, et al
    Medium-term follow up of active surveillance for early prostate cancer at a non-academic institution.
    BJU Int. 2023 Dec 14. doi: 10.1111/bju.16259.
    PubMed     Abstract available
    
    
    November 2023
46. GABRIEL J, Gabriel A, Shafik L, Alanbuki A, et al
    AI in the urology MDM: can ChatGPT suggest EAU guideline-recommended prostate cancer treatments?
    BJU Int. 2023 Nov 27. doi: 10.1111/bju.16240.
    PubMed    
    
    
    
47. SHANMUGASUNDARAM R, Saad J, Heyworth A, Wong V, et al
    Intra-individual comparison of prostate-specific membrane antigen positron emission tomography/computed tomography versus bone scan in detecting skeletal metastasis at prostate cancer diagnosis.
    BJU Int. 2023 Nov 9. doi: 10.1111/bju.16115.
    PubMed     Abstract available
    
    
    October 2023
48. BAGGULEY D, Harewood L, McKenzie D, Ptasznik G, et al
    CONFIRM trial Protocol: The utility of PSMA PET/CT in active surveillance for prostate cancer.
    BJU Int. 2023 Oct 30. doi: 10.1111/bju.16214.
    PubMed     Abstract available
    
    
    
49. KAUFMANN B, Raess E, Schmid FA, Bieri U, et al
    Focal Therapy with High-Intensity Focused Ultrasound for Prostate Cancer: Three Year Outcomes from a Prospective Trial.
    BJU Int. 2023 Oct 27. doi: 10.1111/bju.16213.
    PubMed     Abstract available
    
    
    
50. GEBOERS B, Meijer D, Counter W, Blazevski A, et al
    PSMA-PET in Addition to mpMRI and Biopsies to Select Prostate Cancer Patients for Focal Therapy.
    BJU Int. 2023 Oct 19. doi: 10.1111/bju.16207.
    PubMed     Abstract available
    
    
    
51. TISSOT S, Wynn J, Tran V, Farag M, et al
    Re-defining (18) F-DCFPyl prostate-specific membrane antigen positron emission tomography detected local recurrence from radical prostatectomy histopathology.
    BJU Int. 2023;132:411-419.
    PubMed     Abstract available
    
    
    
52. BOEVE LMS, Bloemendal FT, de Bie KCC, van Haarst EP, et al
    Cancer detection and complications of transperineal prostate biopsy with antibiotics when indicated.
    BJU Int. 2023;132:397-403.
    PubMed     Abstract available
    
    
    September 2023
53. LEHNER F, Crippa A, Sigg S, Eberli D, et al
    Transperineal template saturation and conventional biopsy for stage prediction in prostate cancer.
    BJU Int. 2023 Sep 13. doi: 10.1111/bju.16181.
    PubMed     Abstract available
    
    
    
54. JALLOH M, Cassell A, Niang L, Rebbeck T, et al
    Global Viewpoints: Updates on Prostate cancer in Sub-Saharan Africa.
    BJU Int. 2023 Sep 13. doi: 10.1111/bju.16178.
    PubMed     Abstract available
    
    
    
55. PATTENDEN TA, Thangasamy IA, Ong WL, Samaranayke D, et al
    Barriers and enablers of active surveillance for prostate cancer - a qualitive study of clinicians.
    BJU Int. 2023 Sep 11. doi: 10.1111/bju.16176.
    PubMed     Abstract available
    
    
    
56. KHANNA Y, Chinni V, Gnanasambantham K, O'Sullivan R, et al
    Can (68) Ga-PSMA positron emission tomography and multiparametric MRI guide treatment for biochemical recurrence after radical prostatectomy?
    BJU Int. 2023;132:321-328.
    PubMed     Abstract available
    
    
    August 2023
57. BODAR YJL, Boeve LMS, van Leeuwen PJ, Baars PC, et al
    Using PSMA PET to Guide Prostate Biopsies and Stage Men at High-Risk of Prostate Cancer.
    BJU Int. 2023 Aug 24. doi: 10.1111/bju.16167.
    PubMed     Abstract available
    
    
    
58. DAVIK P, Remmers S, Elschot M, Roobol MJ, et al
    Performance of MRI-based Prostate Cancer Risk Calculators and decision strategies in two large European medical centres.
    BJU Int. 2023 Aug 22. doi: 10.1111/bju.16163.
    PubMed     Abstract available
    
    
    
59. BERNARDINO R, Sayyid RK, Leao R, Zlotta AR, et al
    Increasing Trends of Utilizing Active Surveillance for Gleason 7 (3+4) Prostate Cancer.
    BJU Int. 2023 Aug 22. doi: 10.1111/bju.16162.
    PubMed    
    
    
    
60. SOLANKI AA, Yoo RK, Adams W, Davicioni E, et al
    F-SHARP: A Phase I/II Trial of Focal Salvage HDR Brachytherapy for Radiorecurrent Prostate Cancer.
    BJU Int. 2023 Aug 10. doi: 10.1111/bju.16150.
    PubMed     Abstract available
    
    
    
61. LAUGHLIN BS, Anderson JD, Hobbis D, Armstrong M, et al
    Energy Use in Moderate Hypofractionation and Stereotactic Body Radiotherapy for Prostate Cancer.
    BJU Int. 2023 Aug 8. doi: 10.1111/bju.16151.
    PubMed    
    
    
    
62. FURRER MA, Sathianathen N, Gahl B, Corcoran NM, et al
    Oncological outcomes after attempted nerve sparing radical prostatectomy in patients with high-risk prostate cancer are comparable to standard non-nerve sparing radical prostatectomy: a longitudinal long-term propensity-matched single-centre study.
    BJU Int. 2023 Aug 7. doi: 10.1111/bju.16126.
    PubMed     Abstract available
    
    
    
63. 
    AUA and SUO publish guideline regarding early detection of prostate cancer | Hormone treatment for biochemical recurrence following definitive therapy of prostate cancer | World-famous surgical museum reopens following multimillion pound renovation.
    BJU Int. 2023;132:120-121.
    PubMed    
    
    
    July 2023
64. ALTERBECK M, Thimansson E, Bengtsson J, Baubeta E, et al
    A pilot study of an organised population-based testing programme for prostate cancer.
    BJU Int. 2023 Jul 31. doi: 10.1111/bju.16143.
    PubMed     Abstract available
    
    
    
65. CHEN K, Ong S, Vasundhara K, Mun CK, et al
    Is Genetic testing coming of age in advanced prostate cancer?
    BJU Int. 2023 Jul 27. doi: 10.1111/bju.16139.
    PubMed    
    
    
    
66. SAYYID RK, Klaassen Z, Berlin A, Roy S, et al
    Poly(adenosine diphosphate-ribose) polymerase inhibitor combinations in first-line metastatic castrate-resistant prostate cancer setting: a systematic review and meta-analysis.
    BJU Int. 2023 Jul 17. doi: 10.1111/bju.16130.
    PubMed     Abstract available
    
    
    
67. SAYYID RK, Bernardino R, Al-Daqqaq Z, Tiwari R, et al
    Mesorectal Nodal Metastasis with Seminal Vesicle Invasion in Biochemically Recurrent Prostate Cancer.
    BJU Int. 2023 Jul 11. doi: 10.1111/bju.16123.
    PubMed     Abstract available
    
    
    
68. MASSIE C, Gnanapragasam VJ, Barrett T, Warren A, et al
    Implementation and yield of upfront genomic profiling in a clinical prostate cancer diagnostic pathway.
    BJU Int. 2023 Jul 10. doi: 10.1111/bju.16101.
    PubMed    
    
    
    
69. PARRY MG, Sujenthiran A, Nossiter J, Morris M, et al
    Prostate cancer outcomes following whole-gland and focal high-intensity focused ultrasound.
    BJU Int. 2023 Jul 8. doi: 10.1111/bju.16122.
    PubMed     Abstract available
    
    
    
70. DE PABLOS-RODRIGUEZ P, Claps F, Rebez G, Crespo NV, et al
    Personalized Indocyanine-guided lymphadenectomy for prostate cancer. A randomized Clinical Trial.
    BJU Int. 2023 Jul 6. doi: 10.1111/bju.16117.
    PubMed     Abstract available
    
    
    
71. CUSSENOT O, Cancel-Tassin G, Rao SR, Woodcock DJ, et al
    Aligning germline and somatic mutations in prostate cancer. Are genetics changing practice?
    BJU Int. 2023 Jul 6. doi: 10.1111/bju.16120.
    PubMed     Abstract available
    
    
    
72. YANAGISAWA T, Kawada T, Mori K, Shim SR, et al
    Impact of performance status on efficacy of systemic therapy for prostate cancer: a meta-analysis.
    BJU Int. 2023 Jul 3. doi: 10.1111/bju.16106.
    PubMed     Abstract available
    
    
    
73. 
    Big trials in prostate cancer | predicting drug response in bladder cancer | immune checkpoint inhibitors for urothelial carcinoma | hydrochlorothiazide in the prevention of kidney stone recurrence.
    BJU Int. 2023;132:2-3.
    PubMed    
    
    
    
74. HILL GT, Jeyanthi M, Coomer W, Bryant RJ, et al
    Same-day discharge robot-assisted laparoscopic prostatectomy: feasibility, safety and patient experience.
    BJU Int. 2023;132:92-99.
    PubMed     Abstract available
    
    
    June 2023
75. LIGHT A, Peters M, Reddy D, Kanthabalan A, et al
    External validation of a risk model predicting failure of salvage focal ablation for prostate cancer.
    BJU Int. 2023 Jun 29. doi: 10.1111/bju.16102.
    PubMed     Abstract available
    
    
    
76. JAIN A, Nassour AJ, Symons JL, Chung A, et al
    The effect of different assays on prostate-specific antigen testing.
    BJU Int. 2023;131:689-691.
    PubMed    
    
    
    
77. KANEKO M, Medina LG, Lenon MSL, Sayegh AS, et al
    Transperineal magnetic resonance imaging/transrectal ultrasonography fusion prostate biopsy under local anaesthesia: the 'double-freehand' technique.
    BJU Int. 2023;131:770-774.
    PubMed    
    
    
    
78. BRYANT RJ, Yamamoto H, Eddy B, Kommu S, et al
    Protocol for the TRANSLATE prospective, multicentre, randomised clinical trial of prostate biopsy technique.
    BJU Int. 2023;131:694-704.
    PubMed     Abstract available
    
    
    
79. JIA Z, Chen Z, Chang Y, Wu C, et al
    Sustainable functional urethral reconstruction improves early urinary continence after robot-assisted radical prostatectomy: a randomised controlled trial.
    BJU Int. 2023;131:720-728.
    PubMed     Abstract available
    
    
    
80. FAINBERG J
    Focal therapy using irreversible electroporation: reported successes, with clear limitations, in both primary and salvage settings.
    BJU Int. 2023;131 Suppl 4:34-35.
    PubMed    
    
    
    May 2023
81. LIGHT A, Sarphie DF, Mian R, Li X, et al
    The Leukocyte ImmunoTest for identifying radiorecurrent prostate cancer: a pilot study.
    BJU Int. 2023 May 11. doi: 10.1111/bju.16043.
    PubMed    
    
    
    
82. 
    Issues related to prostate cancer management.
    BJU Int. 2023;131:518-519.
    PubMed    
    
    
    
83. MEISSNER VH, Simson BW, Dinkel A, Schiele S, et al
    Treatment decision regret in long-term survivors after radical prostatectomy: a longitudinal study.
    BJU Int. 2023;131:623-630.
    PubMed     Abstract available
    
    
    April 2023
84. WEI G, Ranasinghe W, Evans M, Bolton D, et al
    Decade-long trends in prostate cancer biopsy grade groups and treatment within a population-based registry.
    BJU Int. 2023 Apr 26. doi: 10.1111/bju.15980.
    PubMed     Abstract available
    
    
    
85. CASTELLO A, Rodriguez-Barranco M, Perez-Gomez B, Chirlaque MD, et al
    High adherence to Western dietary pattern and prostate cancer risk: findings from the EPIC-Spain cohort.
    BJU Int. 2023 Apr 19. doi: 10.1111/bju.16001.
    PubMed     Abstract available
    
    
    
86. ANDRING LM, Abu-Gheida I, Bathala T, Yoder AK, et al
    Definitive local therapy for T4 prostate cancer associated with improved local control and survival.
    BJU Int. 2023 Apr 14. doi: 10.1111/bju.16027.
    PubMed     Abstract available
    
    
    
87. LOPEZ JF, Bryant RJ
    The 'Rapid Access Prostate Imaging and Diagnosis' (RAPID) diagnostic pathway: what is the rush?
    BJU Int. 2023;131:377-379.
    PubMed    
    
    
    
88. KANAGARAJAH A, Hogan D, Yao HH, Dundee P, et al
    A systematic review on the outcomes of local anaesthetic transperineal prostate biopsy.
    BJU Int. 2023;131:408-423.
    PubMed     Abstract available
    
    
    
89. SHORE ND, Stenzl A, Pieczonka C, Klaassen Z, et al
    Impact of darolutamide on local symptoms: pre-planned and post hoc analyses of the ARAMIS trial.
    BJU Int. 2023;131:452-460.
    PubMed     Abstract available
    
    
    March 2023
90. LAZZERI M, Fasulo V, Tinterri C
    Eve's and Adam's rib for prostate cancer screening.
    BJU Int. 2023 Mar 15. doi: 10.1111/bju.15999.
    PubMed    
    
    
    
91. YAXLEY JW
    Focal irreversible electroporation for treatment of primary and radio-recurrent prostate cancer - the evidence is mounting!
    BJU Int. 2023 Mar 6. doi: 10.1111/bju.15987.
    PubMed    
    
    
    
92. 
    Prostate-specific antigen for prostate cancer screening.
    BJU Int. 2023;131:266.
    PubMed    
    
    
    
93. MOROTE J, Pye H, Campistol M, Celma A, et al
    Accurate diagnosis of prostate cancer by combining Proclarix with magnetic resonance imaging.
    BJU Int. 2023 Mar 1. doi: 10.1111/bju.15998.
    PubMed     Abstract available
    
    
    February 2023
94. STROOMBERG HV, Andersen MCM, Helgstrand JT, Larsen SB, et al
    Standardized prostate cancer incidence and mortality rates following initial non-malignant biopsy result.
    BJU Int. 2023 Feb 27. doi: 10.1111/bju.15997.
    PubMed     Abstract available
    
    
    
95. MA TM, Czernin J, Felix C, Alano R, et al
    LUNAR: a randomized phase 2 study of (177) Lutetium-PSMA neoadjuvant to ablative radiotherapy for oligorecurrent prostate cancer (clinical trial protocol).
    BJU Int. 2023 Feb 16. doi: 10.1111/bju.15988.
    PubMed     Abstract available
    
    
    
96. PATEL HD, Koehne EL, Shea SM, Fang AM, et al
    A prostate biopsy risk calculator based on MRI: development and comparison of the Prospective Loyola University multiparametric MRI (PLUM) and Prostate Biopsy Collaborative Group (PBCG) risk calculators.
    BJU Int. 2023;131:227-235.
    PubMed     Abstract available
    
    
    January 2023
97. VICKERS A
    Do not treat Bill Gates for prostate cancer! Algorithmic bias and causality in medical prediction.
    BJU Int. 2023 Jan 30. doi: 10.1111/bju.15951.
    PubMed    
    
    
    
98. CUSSENOT O, Renard-Penna R, Montagne S, Ondet V, et al
    Clinical performance of MRI & biomarkers for prostate cancer diagnosis in men at high genetic risk.
    BJU Int. 2023 Jan 17. doi: 10.1111/bju.15968.
    PubMed     Abstract available
    
    
    
99. GEBOERS B, Scheltema MJ, Blazevski A, Katelaris A, et al
    Median 4-year outcomes of salvage irreversible electroporation for localized radio-recurrent prostate cancer.
    BJU Int. 2023 Jan 3. doi: 10.1111/bju.15948.
    PubMed     Abstract available
    
    
    December 2022
100. HANSEN RS, Biorn SH, Birk-Korch JB, Sheikh SP, et al
     Prevalence of prostate cancer in men with haematuria: A systematic review and meta-analysis.
     BJU Int. 2022 Dec 15. doi: 10.1111/bju.15950.
     PubMed     Abstract available
     
     
     
101. BLAZEVSKI A, Geboers B, Scheltema MJ, Gondoputro W, et al
     Salvage irreversible electroporation for radio recurrent prostate cancer - The prospective FIRE trial.
     BJU Int. 2022 Dec 10. doi: 10.1111/bju.15947.
     PubMed     Abstract available
     
     
     
102. SCHELTEMA MJ, Geboers B, Blazevski A, Doan P, et al
     Median 5-year outcomes of primary focal irreversible electroporation for localized prostate cancer.
     BJU Int. 2022 Dec 10. doi: 10.1111/bju.15946.
     PubMed     Abstract available
     
     
     
103. KOSTER KL, Zumstein V, Suveg K, Jochum W, et al
     Case of the month from the Cantonal Hospital, St Gallen, Switzerland: checkpoint inhibition for recurrent prostate cancer.
     BJU Int. 2022 Dec 5. doi: 10.1111/bju.15847.
     PubMed    
     
     
     
104. BASS EJ, Ahmed HU
     Age-related PSA testing for prostate cancer: NICE recommendation 1.6.3.
     BJU Int. 2022 Dec 5. doi: 10.1111/bju.15859.
     PubMed    
     
     
     
105. BRAIDE K, Kindblom J, Thellenberg Karlsson C, Stattin P, et al
     Risk of severe late toxicity after radiotherapy following radical prostatectomy - a nationwide study.
     BJU Int. 2022;130:799-808.
     PubMed     Abstract available
     
     
     November 2022
106. HOGENHOUT R, Osses DF, Alberts AR, Buizer-Rijksen HG, et al
     Shifting risk-stratified early prostate cancer detection to a primary healthcare setting.
     BJU Int. 2022 Nov 21. doi: 10.1111/bju.15933.
     PubMed     Abstract available
     
     
     
107. KELLY R, Jensen A, Karunaratna N, Wong S, et al
     PSMA PET-CT use prior to systemic therapy in metastatic Castration-Resistant Prostate Cancer (mCRPC).
     BJU Int. 2022 Nov 13. doi: 10.1111/bju.15930.
     PubMed    
     
     
     
108. DOAN P, Counter W, Papa N, Sheehan-Dare G, et al
     Synchronous versus independent reading of PSMA-PET and MRI to improve diagnosis for prostate cancer.
     BJU Int. 2022 Nov 13. doi: 10.1111/bju.15929.
     PubMed     Abstract available
     
     
     
109. CUSSENOT O, Cancel-Tassin G, Comperat E, Benbouzid S, et al
     Total pelvic exenteration surgery for loco-regionally advanced prostate cancer, is it justifiable?
     BJU Int. 2022;130:582-585.
     PubMed    
     
     
     
110. VAN DER SLOT MA, den Bakker MA, Tan TSC, Remmers S, et al
     NeuroSAFE in radical prostatectomy increases the rate of nerve-sparing surgery without affecting oncological outcome.
     BJU Int. 2022;130:628-636.
     PubMed     Abstract available
     
     
     
111. LAWRENTSCHUK N
     Funding of all issues related to prostate cancer treatment should be a priority and have equal access - a key to survivorship.
     BJU Int. 2022;130 Suppl 3:4.
     PubMed    
     
     
     
112. YAXLEY WJ, Mackean J, Desai DJ, Tsang G, et al
     Oncological and urinary outcomes following low-dose-rate brachytherapy with a median follow-up of 11.8 years.
     BJU Int. 2022;130 Suppl 3:40-45.
     PubMed     Abstract available
     
     
     
113. ROBERTS MJ, Chatfield MD, Hruby G, Nandurkar R, et al
     Event-free survival after radical prostatectomy according to prostate-specific membrane antigen-positron emission tomography and European Association of Urology biochemical recurrence risk groups.
     BJU Int. 2022;130 Suppl 3:32-39.
     PubMed     Abstract available
     
     
     September 2022
114. ELDRED-EVANS D, Connor MJ, Bertoncelli Tanaka M, Bass E, et al
     The Rapid Assessment for Prostate Imaging and Diagnosis (RAPID) prostate cancer diagnostic pathway.
     BJU Int. 2022 Sep 22. doi: 10.1111/bju.15899.
     PubMed     Abstract available
     
     
     
115. VEERMAN H, Donswijk M, Bekers E, Bodar YJL, et al
     The Oncological Characteristics of Non-PSMA-Expressing Primary Prostate Cancer on preoperative PSMA PET/CT.
     BJU Int. 2022 Sep 19. doi: 10.1111/bju.15896.
     PubMed    
     
     
     
116. EHRET F, Hofmann T, Furweger C, Kufeld M, et al
     Single-fraction PSMA-PET- and multiparametric MRI-guided SBRT for Prostate Cancer Local Recurrences.
     BJU Int. 2022 Sep 17. doi: 10.1111/bju.15894.
     PubMed     Abstract available
     
     
     
117. HAEUSER L, Nguyen DD, Trinh QD
     Prostate cancer and kidney transplantation - exclusion or coexistence?
     BJU Int. 2022 Sep 12. doi: 10.1111/bju.15074.
     PubMed    
     
     
     
118. ORRASON AW, Styrke J, Garmo H, Stattin P, et al
     Evidence of cancer progression as the cause of death in men with prostate cancer in Sweden.
     BJU Int. 2022 Sep 11. doi: 10.1111/bju.15891.
     PubMed     Abstract available
     
     
     
119. ICZKOWSKI KA, Molina M, Egevad L, Bostwick DG, et al
     Low-Grade Prostate Cancer Should Still be Labeled Cancer.
     BJU Int. 2022 Sep 9. doi: 10.1111/bju.15886.
     PubMed    
     
     
     
120. ONG S, Chen K, Grummet J, Yaxley J, et al
     Guidelines of guidelines: Focal therapy for prostate cancer, is it time for consensus?
     BJU Int. 2022 Sep 9. doi: 10.1111/bju.15883.
     PubMed     Abstract available
     
     
     
121. MEIJER D, Ettema RH, van Leeuwen PJ, van der Kwast TH, et al
     The prognostic value of lymph node staging with prostate-specific membrane antigen (PSMA) positron emission tomography/computed tomography (PET/CT) and extended pelvic lymph node dissection in node-positive patients with prostate cancer.
     BJU Int. 2022 Sep 7. doi: 10.1111/bju.15881.
     PubMed     Abstract available
     
     
     
122. 
     Updates on bladder, kidney and prostate cancers.
     BJU Int. 2022;130:275-276.
     PubMed    
     
     
     
123. RAHOTA RG, Salin A, Gautier JR, Almeras C, et al
     A prehabilitation programme implemented before robot-assisted radical prostatectomy improves peri-operative outcomes and continence recovery.
     BJU Int. 2022;130:357-363.
     PubMed     Abstract available
     
     
     August 2022
124. EXTERKATE L, Wegelin O, Barentsz JO, van der Leest MG, et al
     Incidence of significant prostate cancer after negative MRI and systematic biopsy in the FUTURE trial.
     BJU Int. 2022 Aug 22. doi: 10.1111/bju.15876.
     PubMed     Abstract available
     
     
     
125. SCHNEIDER A, Bulafka J, Arisi MF, Li L, et al
     Case of the month from the Thomas Jefferson Sidney Kimmel medical college, Philadelphia, USA. Prostatic abscess and advanced prostate cancer: considering malignancy in the differential diagnosis.
     BJU Int. 2022;130:181-185.
     PubMed    
     
     
     July 2022
126. WILLIAMS IS, Perera S, Murphy DG, Corcoran NM, et al
     Active surveillance versus enzalutamide for low-risk prostate cancer- was it really a trial we needed?
     BJU Int. 2022 Jul 25. doi: 10.1111/bju.15860.
     PubMed    
     
     
     
127. RUSHWORTH LK, Loveridge C, Salji M, MacLeod M, et al
     Phase II Proof of Concept Study of Atorvastatin in Castration Resistant Prostate Cancer.
     BJU Int. 2022 Jul 18. doi: 10.1111/bju.15851.
     PubMed     Abstract available
     
     
     
128. 
     FDA approves new agent for the treatment of metastatic prostate cancer.
     BJU Int. 2022;130:3-4.
     PubMed    
     
     
     
129. PARRY MG, Skolarus TA, Nossiter J, Sujenthiran A, et al
     Urinary incontinence and use of incontinence surgery after radical prostatectomy: a national study using patient-reported outcomes.
     BJU Int. 2022;130:84-91.
     PubMed     Abstract available
     
     
     
130. SETIA SA, Smith J, Cendo D, Yoder J, et al
     Outcomes of freehand transperineal prostate biopsy with omission of antibiotic prophylaxis.
     BJU Int. 2022;130:54-61.
     PubMed     Abstract available
     
     
     June 2022
131. DJURHUUS SS, Simonsen C, Toft BG, Thomsen SN, et al
     Exercise Training to Increase Tumor NK Cell Infiltration in Men with Localized Prostate Cancer: an RCT.
     BJU Int. 2022 Jun 26. doi: 10.1111/bju.15842.
     PubMed     Abstract available
     
     
     
132. AGGARWAL A, Han L, Tree A, Lewis D, et al
     Impact of centralisation of prostate cancer services on the choice of radical treatment.
     BJU Int. 2022 Jun 20. doi: 10.1111/bju.15830.
     PubMed     Abstract available
     
     
     
133. SUSHENTSEV N, Barrett T, Warren AY, Gnanapragasam VJ, et al
     How and when should radiologists report T-staging on MRI in patients with prostate cancer?
     BJU Int. 2022 Jun 13. doi: 10.1111/bju.15824.
     PubMed    
     
     
     
134. HARVEY M, Ong WL, Chao M, Udovicich C, et al
     Comprehensive review of hydrogel spacers prior to radiation therapy for prostate cancer.
     BJU Int. 2022 Jun 10. doi: 10.1111/bju.15821.
     PubMed     Abstract available
     
     
     
135. LANGLEY S, Eden C, Perry M, Patil K, et al
     Robot-assisted salvage seminal vesicle excision for isolated recurrence after low-dose-rate prostate brachytherapy.
     BJU Int. 2022;129:731-736.
     PubMed     Abstract available
     
     
     
136. LAWRENTSCHUK N
     Sensible government decisions on funding for imaging can change practice and deliver better care for men with prostate cancer.
     BJU Int. 2022;130 Suppl 1:4.
     PubMed    
     
     
     
137. PERRY E, Talwar A, Taubman K, Ng M, et al
     Pathological predictors of (18) F-DCFPyL prostate-specific membrane antigen-positive recurrence after radical prostatectomy.
     BJU Int. 2022;130 Suppl 1:28-36.
     PubMed     Abstract available
     
     
     May 2022
138. O'BRIEN JS, McVey A, Kelly BD, Jenjitranant P, et al
     PSMA PET-CT Funding Grants Free Access to Superior Staging for Australian Men with Prostate Cancer.
     BJU Int. 2022 May 16. doi: 10.1111/bju.15773.
     PubMed    
     
     
     
139. RAHOTA RG, Diamand R, Malavaud B, Fiard G, et al
     Pathological features of Prostate Imaging Reporting and Data System (PI-RADS) 3 MRI lesions in biopsy and radical prostatectomy specimens.
     BJU Int. 2022;129:621-626.
     PubMed     Abstract available
     
     
     
140. HAYNE D, Grummet J, Espinoza D, McCombie SP, et al
     'Pain-free TRUS B': a phase 3 double-blind placebo-controlled randomized trial of methoxyflurane with periprostatic local anaesthesia to reduce the discomfort of transrectal ultrasonography-guided prostate biopsy (ANZUP 1501).
     BJU Int. 2022;129:591-600.
     PubMed     Abstract available
     
     
     April 2022
141. NATHAN A, Morris M, Parry MG, Berry B, et al
     Interventions for obstructive uropathy in advanced prostate cancer: a population-based study.
     BJU Int. 2022 Apr 29. doi: 10.1111/bju.15766.
     PubMed     Abstract available
     
     
     
142. VAN RIEL LAMJG, Geboers B, Kabaktepe E, Blazevski A, et al
     Outcomes of Salvage Radical Prostatectomy after initial IRE Treatment for Recurrent Prostate Cancer.
     BJU Int. 2022 Apr 27. doi: 10.1111/bju.15759.
     PubMed     Abstract available
     
     
     
143. BOKU H, Kaneko M, Yamada Y, Morinaga Y, et al
     Microwave for focal therapy of prostate cancer: Non-clinical study and exploratory clinical trial.
     BJU Int. 2022 Apr 18. doi: 10.1111/bju.15749.
     PubMed     Abstract available
     
     
     
144. LANE JA, Donovan JL, Young GJ, Davis M, et al
     Functional and quality of life outcomes of localised prostate cancer treatments (ProtecT study).
     BJU Int. 2022 Apr 3. doi: 10.1111/bju.15739.
     PubMed     Abstract available
     
     
     
145. CHASE EC, Bryant AK, Sun Y, Jackson WC, et al
     Development and Validation of a Life Expectancy Calculator for U.S. Prostate Cancer Patients.
     BJU Int. 2022 Apr 3. doi: 10.1111/bju.15740.
     PubMed     Abstract available
     
     
     
146. PTASZNIK G, Papa N, Kelly BD, Thompson J, et al
     High PSMA PET SUVmax in PI-RADS 4 or 5 men confers a high probability of significant prostate cancer.
     BJU Int. 2022 Apr 1. doi: 10.1111/bju.15736.
     PubMed    
     
     
     
147. 
     Prostate cancer and ethnicity, personalised treatment for renal masses and oral testosterone for hypogonadism.
     BJU Int. 2022;129:422.
     PubMed    
     
     
     
148. LUZZAGO S, Piccinelli ML, Mistretta FA, Bianchi R, et al
     Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates.
     BJU Int. 2022;129:524-533.
     PubMed     Abstract available
     
     
     March 2022
149. 
     New guidance regarding the diagnosis and risk stratification of patients with prostate cancer.
     BJU Int. 2022;129:304-305.
     PubMed    
     
     
     
150. KLEIN RJ
     Polygenic risk scores and prostate cancer screening: a recipe for more overdiagnosis?
     BJU Int. 2022;129:271.
     PubMed    
     
     
     
151. FERRARO S, Biganzoli EM
     Association between total prostate-specific antigen (tPSA), free/tPSA, and prostate cancer mortality.
     BJU Int. 2022;129:418.
     PubMed    
     
     
     
152. MARTIN RM, Dixon P, Turner E, Keeney E, et al
     Contribution of the Cluster randomised triAl of PSA testing for Prostate cancer (CAP) to the ongoing debate on the value of prostate cancer screening.
     BJU Int. 2022;129:269-270.
     PubMed    
     
     
     
153. TEYATEETI A, Grossman C, Kollmeier MA, Fiasconaro M, et al
     Influence of hydrogel spacer placement with prostate brachytherapy on rectal and urinary toxicity.
     BJU Int. 2022;129:337-344.
     PubMed     Abstract available
     
     
     
154. BJORKLUND J, Stattin P, Ronmark E, Aly M, et al
     The 90-day cause-specific mortality after radical prostatectomy: a nationwide population-based study.
     BJU Int. 2022;129:318-324.
     PubMed     Abstract available
     
     
     
155. ZHAO J, Sun G, Zhu S, Dai J, et al
     Circulating tumour DNA reveals genetic traits of patients with intraductal carcinoma of the prostate.
     BJU Int. 2022;129:345-355.
     PubMed     Abstract available
     
     
     
156. PASCHEN U, Sturtz S, Fleer D, Lampert U, et al
     Assessment of prostate-specific antigen screening: an evidence-based report by the German Institute for Quality and Efficiency in Health Care.
     BJU Int. 2022;129:280-289.
     PubMed     Abstract available
     
     
     February 2022
157. BODAR YJL, Veerman H, Meijer D, de Bie K, et al
     Standardised Uptake Values as Determined on PSMA PET/CT is associated with Oncological Outcomes in Prostate Cancer Patients.
     BJU Int. 2022 Feb 15. doi: 10.1111/bju.15710.
     PubMed     Abstract available
     
     
     
158. DASON S, Vertosick EA, Udo K, Sjoberg DD, et al
     Clinical utility of subclassifying positive surgical margins at radical prostatectomy.
     BJU Int. 2022;129:194-200.
     PubMed     Abstract available
     
     
     
159. SORCE G, Stabile A, Luciano R, Motterle G, et al
     Multiparametric magnetic resonance imaging of the prostate underestimates tumour volume of small visible lesions.
     BJU Int. 2022;129:201-207.
     PubMed     Abstract available
     
     
     January 2022
160. NOSSITER J, Morris M, Parry MG, Sujenthiran A, et al
     Impact of the Covid-19 pandemic on the diagnosis and treatment of men with prostate cancer.
     BJU Int. 2022 Jan 25. doi: 10.1111/bju.15699.
     PubMed     Abstract available
     
     
     
161. ONG WL, Thangasamy I, Murphy D, Pritchard E, et al
     Large variation in conservative management for low-risk prostate cancer in Australia and New Zealand.
     BJU Int. 2022 Jan 25. doi: 10.1111/bju.15698.
     PubMed    
     
     
     
162. BRATT O
     Integrating magnetic resonance imaging and prostate-specific membrane antigen positron emission tomography/computed tomography results into prostate cancer treatment decision making.
     BJU Int. 2022;129:3-4.
     PubMed    
     
     
     
163. GRAY WK, Day J, Briggs TWR, Harrison S, et al
     An observational study of volume-outcome effects for robot-assisted radical prostatectomy in England.
     BJU Int. 2022;129:93-103.
     PubMed     Abstract available
     
     
     December 2021
164. RANNIKKO A, Leht M, Mirtti T, Kenttamies A, et al
     Population-based randomized trial of screening for clinically significant prostate cancer ProScreen: pilot study.
     BJU Int. 2021 Dec 27. doi: 10.1111/bju.15683.
     PubMed     Abstract available
     
     
     
165. SOORIAKUMARAN P, Wilson C, Rombach I, Hassanali N, et al
     Feasibility and safety of radical prostatectomy for oligo-metastatic prostate cancer: TRoMbone trial.
     BJU Int. 2021 Dec 8. doi: 10.1111/bju.15669.
     PubMed     Abstract available
     
     
     
166. VEERMAN H, Donswijk M, Bekers E, Olde Heuvel J, et al
     Clinical Characteristics of Primary Non-PSMA-Expressing Prostate Cancer on preoperative PSMA PET/CT.
     BJU Int. 2021 Dec 1. doi: 10.1111/bju.15664.
     PubMed     Abstract available
     
     
     
167. 
     Acute Urinary Retention and Cancer; Is It All About the Prostate?
     BJU Int. 2021;128:660.
     PubMed    
     
     
     
168. LENFANT L, Corrigan D, Beksac AT, Schwen Z, et al
     Learning curve analysis of single-port robot-assisted extraperitoneal prostatectomy using the cumulative sum (CUSUM) method.
     BJU Int. 2021;128:688-691.
     PubMed    
     
     
     
169. SANDAHL M, Pedersen BG, Ulhoi BP, Borre M, et al
     Risk stratification in men with a negative prostate biopsy: an interim analysis of a prospective cohort study.
     BJU Int. 2021;128:702-712.
     PubMed     Abstract available
     
     
     
170. HENNES DMZB, Sewell J, Kerger M, Hovens CM, et al
     The modified International Society of Urological Pathology system improves concordance between biopsy and prostatectomy tumour grade.
     BJU Int. 2021;128 Suppl 3:45-51.
     PubMed     Abstract available
     
     
     November 2021
171. JOHN JB, Pascoe J, Fowler S, Walton T, et al
     A nationwide trend away from radical prostatectomy for Gleason grade group 1 prostate cancer.
     BJU Int. 2021 Nov 26. doi: 10.1111/bju.15656.
     PubMed     Abstract available
     
     
     
172. ROSENBERG JE, Jung JH, Lee H, Lee S, et al
     Posterior musculofascial reconstruction in robotic-assisted laparoscopic prostatectomy for the treatment of clinically localized prostate cancer: a Cochrane Review.
     BJU Int. 2021 Nov 26. doi: 10.1111/bju.15657.
     PubMed     Abstract available
     
     
     
173. LEE V, An Y, Park HS, Yu JB, et al
     Emergency Department Visits for Radiation Cystitis Among Patients with a Prostate Cancer History.
     BJU Int. 2021 Nov 22. doi: 10.1111/bju.15650.
     PubMed     Abstract available
     
     
     
174. KANNAN A, Clouston D, Frydenberg M, Ilic D, et al
     Neuroendocrine cells in prostate cancer correlate with poor outcomes: A systematic review and meta-analysis.
     BJU Int. 2021 Nov 16. doi: 10.1111/bju.15647.
     PubMed     Abstract available
     
     
     
175. HOFBAUER SL, Luger F, Harland N, Plage H, et al
     A Non-Inferiority Comparative Analysis of Micro-Ultrasound and MRI Targeted Biopsy in Men at Risk of Prostate Cancer.
     BJU Int. 2021 Nov 13. doi: 10.1111/bju.15635.
     PubMed     Abstract available
     
     
     
176. IP CCK, Kealey J, Davis ID, Sengupta S, et al
     Impacts of the COVID-19 Pandemic on Early Detection of Prostate Cancer in Australia.
     BJU Int. 2021 Nov 9. doi: 10.1111/bju.15631.
     PubMed     Abstract available
     
     
     
177. HEESTERMAN BL, van der Poel HG, Schoots IG, Mehra N, et al
     Prognostic importance of concomitant non-regional lymph node and bone metastases in men with newly diagnosed metastatic prostate cancer.
     BJU Int. 2021 Nov 6. doi: 10.1111/bju.15632.
     PubMed     Abstract available
     
     
     
178. PALUDO AO, Knijnik PG, Silva Neto B, Berger M, et al
     Initial experience with first postoperative day Foley catheter removal after robot-assisted radical prostatectomy.
     BJU Int. 2021;128:555-557.
     PubMed    
     
     
     
179. TULLY KH, Schulmeyer M, Hanske J, Reike MJ, et al
     Identification of patients at risk for biochemical recurrence after radical prostatectomy with intra-operative frozen section.
     BJU Int. 2021;128:598-606.
     PubMed     Abstract available
     
     
     
180. ZHANG Z, Lampotang S, Yu Y, Acar YA, et al
     Attitude is everything: keep probe pitch neutral during side-fire prostate biopsy. A simulator study.
     BJU Int. 2021;128:615-624.
     PubMed     Abstract available
     
     
     October 2021
181. HUYNH LM, Huang E, Towe M, Liang K, et al
     Evidence for integration of total and free testosterone levels in management of prostate cancer.
     BJU Int. 2021 Oct 30. doi: 10.1111/bju.15626.
     PubMed     Abstract available
     
     
     
182. POULIOT F, Beauregard JM, Saad F, Trudel D, et al
     The 3TMPO study protocol: triple-tracer PET imaging of metastatic castration-resistant prostate cancer.
     BJU Int. 2021 Oct 21. doi: 10.1111/bju.15621.
     PubMed     Abstract available
     
     
     
183. WITT JH, Friedrich M, Jandrig B, Porsch M, et al
     Molecular margin status after radical prostatectomy using glutathione S-transferase P1 (GSTP1) promoter hypermethylation.
     BJU Int. 2021 Oct 17. doi: 10.1111/bju.15618.
     PubMed     Abstract available
     
     
     
184. MARRA G, Calleris G, Marquis A, Oderda M, et al
     Reply to letter by Montorsi et al. Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
     BJU Int. 2021;128:524.
     PubMed    
     
     
     
185. MONTORSI F, Stabile A, Gandaglia G, Fossati N, et al
     Re: Marra et al. 'Transperineal freehand multiparametric MRI fusion targeted biopsies under local anaesthesia for prostate cancer diagnosis: a multicentre prospective study of 1014 cases'.
     BJU Int. 2021;128:523.
     PubMed    
     
     
     
186. GULDBAEK MV, Fode M, Jensen CFS, Sonksen J, et al
     'Case of the Month' from Herlev and Gentofte Hospital, Denmark: metastatic prostate cancer in a man with late-onset hypogonadism following testosterone-replacement therapy.
     BJU Int. 2021;128:428-430.
     PubMed    
     
     
     
187. KELLY R, Anton A, Wong S, Shapiro J, et al
     Real-world use of first-generation antiandrogens: impact on patient outcomes and subsequent therapies in metastatic castration-resistant prostate cancer.
     BJU Int. 2021;128 Suppl 1:18-26.
     PubMed     Abstract available
     
     
     
188. CATHCART P, Ribeiro L, Moore C, Ahmed HU, et al
     Outcomes of the RAFT trial: robotic surgery after focal therapy.
     BJU Int. 2021;128:504-510.
     PubMed     Abstract available
     
     
     September 2021
189. LIGHT A, Burns-Cox N, Maccormick A, John J, et al
     The diagnostic impact of UK regional variations in age-specific prostate-specific antigen guidelines.
     BJU Int. 2021;128:298-300.
     PubMed    
     
     
     August 2021
190. URIBE-LEWIS S, Uribe J, Bourke V, Deering C, et al
     Long-term survival after LDR Brachytherapy for Prostate Cancer: the Royal Surrey experience.
     BJU Int. 2021 Aug 27. doi: 10.1111/bju.15585.
     PubMed     Abstract available
     
     
     
191. MOROTE J, Schwartzmann I, Celma A, Roche S, et al
     The current recommendation for the management of isolated high-grade prostatic intraepithelial neoplasia.
     BJU Int. 2021 Aug 10. doi: 10.1111/bju.15568.
     PubMed     Abstract available
     
     
     
192. DOAN P, Graham P, Lahoud J, Remmers S, et al
     A comparison of prostate cancer prediction models in men undergoing both magnetic resonance imaging and transperineal biopsy: Are the models still relevant?
     BJU Int. 2021 Aug 9. doi: 10.1111/bju.15554.
     PubMed     Abstract available
     
     
     
193. ISRAEL B, Immerzeel J, van der Leest M, Hannink G, et al
     Clinical Implementation of Pre-biopsy MRI-Pathways for the Diagnosis of Prostate Cancer.
     BJU Int. 2021 Aug 6. doi: 10.1111/bju.15562.
     PubMed     Abstract available
     
     
     
194. 
     FDA approves a second PSMA targeting agent for PET imaging in men with prostate cancer.
     BJU Int. 2021;128:127-130.
     PubMed    
     
     
     
195. DUDDERIDGE TJ
     Multiparametric magnetic resonance imaging - a crucial imaging tool for considering and planning prostate cancer focal therapy.
     BJU Int. 2021;128:125-126.
     PubMed    
     
     
     
196. INOUE T, Sasaki T, Kato M, Masui S, et al
     Warning against second-generation antiandrogen for metastatic castration sensitive prostate cancer.
     BJU Int. 2021 Aug 1. doi: 10.1111/bju.15561.
     PubMed     Abstract available
     
     
     
197. 
     Chemotherapeutic treatment of MCRPC and non-MCRPC.
     BJU Int. 2021;128:153-154.
     PubMed    
     
     
     
198. TAMIR S, Hermann D, Margel D, Gavrielli S, et al
     Indications for prostate multiparametric magnetic resonance imaging: changes over 7 years in a single referral centre.
     BJU Int. 2021;128:165-167.
     PubMed    
     
     
     July 2021
199. BUELENS S, Poelaert F, Claeys T, De Bleser E, et al
     Multicentric Prospective Local Treatment of Metastatic Prostate Cancer (LoMP) Study.
     BJU Int. 2021 Jul 21. doi: 10.1111/bju.15553.
     PubMed     Abstract available
     
     
     
200. KAMRAN SC, Zietman AL
     Radiation Treatment in Prostate Cancer: Covering the Waterfront.
     BJU Int. 2021 Jul 17. doi: 10.1111/bju.15550.
     PubMed     Abstract available
     
     
     
201. KREIS K, Horenkamp-Sonntag D, Schneider U, Zeidler J, et al
     Safety and survival of docetaxel and cabazitaxel in metastatic castration-resistant prostate cancer.
     BJU Int. 2021 Jul 9. doi: 10.1111/bju.15542.
     PubMed     Abstract available
     
     
     
202. BENAFIF S, Ni Raghallaigh H, McGrowder E, Saunders EJ, et al
     The BARCODE1 Pilot: a feasibility study of using germline SNPs to target prostate cancer screening.
     BJU Int. 2021 Jul 2. doi: 10.1111/bju.15535.
     PubMed     Abstract available
     
     
     
203. MOTTRIE A, Mazzone E, Wiklund P, Graefen M, et al
     Objective assessment of intraoperative skills for robot-assisted radical prostatectomy (RARP): results from the ERUS Scientific and Educational Working Groups Metrics Initiative.
     BJU Int. 2021;128:103-111.
     PubMed     Abstract available
     
     
     
204. SINGH S, Sandhu P, Beckmann K, Santaolalla A, et al
     Negative first follow-up prostate biopsy on active surveillance is associated with decreased risk of upgrading, suspicion of progression and converting to active treatment.
     BJU Int. 2021;128:72-78.
     PubMed     Abstract available
     
     
     June 2021
205. MORI K, Mostafaei H, Sari Motlagh R, Pradere B, et al
     Systemic Therapies for Metastatic Hormone-Sensitive Prostate Cancer: Network Meta-Analysis.
     BJU Int. 2021 Jun 25. doi: 10.1111/bju.15507.
     PubMed     Abstract available
     
     
     
206. BERTONCELLI TANAKA M, Sahota K, Burn J, Falconer A, et al
     Prostate cancer in transgender women: what does a urologist need to know?
     BJU Int. 2021 Jun 22. doi: 10.1111/bju.15521.
     PubMed     Abstract available
     
     
     
207. ALBERTSEN P
     Prostate cancer: the interplay between genetics and the environment.
     BJU Int. 2021;127:615-616.
     PubMed    
     
     
     
208. YAXLEY J
     Letter to the Editor BJUI in response to Montorsi et al.: Histological comparison between predictive value of preoperative 3-T multiparametric MRI and (68) Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node di
     BJU Int. 2021;127:747.
     PubMed    
     
     
     
209. DIRIE J, Mahesan T, Hart E, Janardanan S, et al
     Delivering safe and timely cancer care during COVID-19: lessons and successes from the transition period.
     BJU Int. 2021;127:633-635.
     PubMed    
     
     
     
210. TANDOGDU Z, Collins J, Shaw G, Rohn J, et al
     Management of patients who opt for radical prostatectomy during the coronavirus disease 2019 (COVID-19) pandemic: an international accelerated consensus statement.
     BJU Int. 2021;127:729-741.
     PubMed     Abstract available
     
     
     
211. DINNEEN E, Haider A, Grierson J, Freeman A, et al
     NeuroSAFE frozen section during robot-assisted radical prostatectomy: peri-operative and histopathological outcomes from the NeuroSAFE PROOF feasibility randomized controlled trial.
     BJU Int. 2021;127:676-686.
     PubMed     Abstract available
     
     
     May 2021
212. EMMETT L, Subramaniam S, Joshua A, Crumbaker M, et al
     ENZA-p trial protocol: A randomised phase II trial using PSMA as a therapeutic target and prognostic indicator in men with metastatic castration-resistant prostate cancer treated with enzalutamide (ANZUP 1901).
     BJU Int. 2021 May 24. doi: 10.1111/bju.15491.
     PubMed     Abstract available
     
     
     
213. MEIJER D, van Leeuwen PJ, Donswijk ML, Boellaard TN, et al
     Predicting Early Outcomes in Intermediate and High Risk Prostate Cancer Patients using PSMA PET and MRI.
     BJU Int. 2021 May 24. doi: 10.1111/bju.15492.
     PubMed     Abstract available
     
     
     
214. KNIPPER S, Tilki D, Graefen M, Maurer T, et al
     Early prostate cancer recurrence with PSMA PET positive unilateral pelvic lesion(s): is one-sided salvage extended lymph node dissection enough? (ProSTone, NCT04271579).
     BJU Int. 2021 May 22. doi: 10.1111/bju.15485.
     PubMed     Abstract available
     
     
     
215. O'CALLAGHAN M, Papa N, Pase M, Frydenberg M, et al
     Patterns of care for prostate cancer treatment and improving outcomes - are national registries the answer?
     BJU Int. 2021 May 11. doi: 10.1111/bju.15366.
     PubMed    
     
     
     
216. 
     Recent advances in the diagnosis and management of prostate cancer.
     BJU Int. 2021;127:518-519.
     PubMed    
     
     
     
217. URKMEZ A, Ward JF, Choi H, Troncoso P, et al
     Temporal learning curve of a multidisciplinary team for magnetic resonance imaging/transrectal ultrasonography fusion prostate biopsy.
     BJU Int. 2021;127:524-527.
     PubMed    
     
     
     
218. INOUE S, Hayashi T, Teishima J, Matsubara A, et al
     Longitudinal evaluation of the frequency of sexual intercourse and sexual activity in patients after nerve-sparing robot-assisted laparoscopic radical prostatectomy.
     BJU Int. 2021;127:560-566.
     PubMed     Abstract available
     
     
     
219. TUTOLO M, Bruyneel L, Van der Aa F, Van Damme N, et al
     A novel tool to predict functional outcomes after robot-assisted radical prostatectomy and the value of additional surgery for incontinence.
     BJU Int. 2021;127:575-584.
     PubMed     Abstract available
     
     
     
220. TIMM B, Farag M, Liodakis P, Angus D, et al
     Vesico-urethral anastomosis sampling: a forgotten tool for guiding salvage radiation after radical prostatectomy.
     BJU Int. 2021;127 Suppl 1:23-29.
     PubMed     Abstract available
     
     
     
221. JOHN A, John H, Catterwell R, Selth LA, et al
     Primary Gleason grade and Gleason grade group at positive surgical margins: a systematic review and meta-analysis.
     BJU Int. 2021;127 Suppl 1:13-22.
     PubMed     Abstract available
     
     
     April 2021
222. CHILUKURI S, Murthy V
     Adjuvant radiation for prostate cancer: Too early to abandon?
     BJU Int. 2021 Apr 9. doi: 10.1111/bju.15422.
     PubMed     Abstract available
     
     
     
223. LUNDGREN PO, Kjellman A, Norming U, Gustafsson O, et al
     Association Between One-time Prostate-Specific Antigen (PSA) Test with Free/Total PSA and Prostate Cancer Mortality: A 30-year Prospective Cohort Study.
     BJU Int. 2021 Apr 3. doi: 10.1111/bju.15417.
     PubMed     Abstract available
     
     
     
224. XU AJ, Taylor J, Gao T, Mihalcea R, et al
     TikTok and Prostate Cancer: Misinformation and Quality of Information using Validated Questionnaires.
     BJU Int. 2021 Apr 2. doi: 10.1111/bju.15403.
     PubMed     Abstract available
     
     
     
225. GALFANO A, Secco S, Dell'Oglio P, Rha K, et al
     Retzius-sparing robot-assisted radical prostatectomy: early learning curve experience in three continents.
     BJU Int. 2021;127:412-417.
     PubMed     Abstract available
     
     
     March 2021
226. BARRETT T, Padhani AR, Patel A, Ahmed HU, et al
     Certification in reporting multiparametric magnetic resonance imaging of the prostate: recommendations of a UK consensus meeting.
     BJU Int. 2021;127:304-306.
     PubMed    
     
     
     
227. NYBERG M, Sjoberg DD, Carlsson SV, Wilderang U, et al
     Surgeon heterogeneity significantly affects functional and oncological outcomes after radical prostatectomy in the Swedish LAPPRO trial.
     BJU Int. 2021;127:361-368.
     PubMed     Abstract available
     
     
     February 2021
228. HUANG MM, Su ZT, Becker REN, Pavlovich CP, et al
     Complications after open and robot-assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial.
     BJU Int. 2021;127:190-197.
     PubMed     Abstract available
     
     
     January 2021
229. AHO T, Al-Hayek S, Winterbottom A, Koo B, et al
     'Case of the Month' from Cambridge University, UK: managing intractable bleeding from a 375 cc prostate in an anti-coagulated patient.
     BJU Int. 2021;127:37-40.
     PubMed    
     
     
     
230. 
     World News.
     BJU Int. 2021;127:1-3.
     PubMed    
     
     
     
231. COVAS MOSCHOVAS M, Bhat S, Onol F, Rogers T, et al
     Early outcomes of single-port robot-assisted radical prostatectomy: lessons learned from the learning-curve experience.
     BJU Int. 2021;127:114-121.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.